ABSTRACT
Once the potential for the pregnancy loss in patients with aPL syndrome was recognized, it was suggested that fetal wastage could be prevented by treatments designed to suppress antibody production and to prevent recurrent thrombosis (7 ,16). Lubbe et al. reported that women who had never previously completed pregnancy could become mothers if treated with aspirin and prednisone (7). Multiple other reports followed leading to the conclusion that the appropriate treatment for pregnant women with the phospholipid syndrome was anticoagulation and corticosteroids (16,17), even though large, randomized controlled trials had never been performed. This resulted in many women with aPL receiving these treatments throughout pregnancy regardless of their previous medical or obstetric histories. UnfortUnately, some patients developed significant maternal morbidity, including toxemia of pregnancy, gestational diabetes, aseptic necrosis of various joints, and even cataracts (18,19).
